18. Owings MP, Lawrence L. Detailed diagnosis and procedures. National Hospital Discharge Survey, 1997. National Center for Health Statistics. Vital Health Slat 13(145). 1999.
19. Enright PL, Lcbowitz MD, Cockcroft DW. Physiologic measures: pulmonary function tests. Am J Respir Crit Care Med 1994;149:S9-S18.
20. Hogg JC, Macklem PT, Thurlbeck WM. Site and nature of airway obstruction in chronic obstructive lung disease. N Engi J Med 1968;278:1355-1360.
21. Burrows B. Course and prognosis of patients with chronic airways obstruction. Chest 1980;77:250-251.
22. Bhagat R, Kaira S, Swystun VA, Cockcroft OW. Rapid onset of tolerance to the bronchoprotecdvc effect of salmeterol. Chest 1995: 108:1235-1239.
23. Lipworth BJ. Airway subsensirivity with long-acting ft ago-nists. Is there cause for concern? Drug Saf 1997,16:295-308.
24. FitzGerald JM, Chapman KR, Delia Cioppa G, et al. Sustained bronchoprotecdon, bronchodilaiarion, and symptom control during regular fonnoterol use in asthma of moderate or greater severity. The Canadian FQ/OD1 Study Group. J Allergy Clin Immunol 1999;103:427-435.
25. Hui K.K. Connoly ME. Tashkin DP. Reversal of human lyra-phocyte p-adrenoccptor descnsitization by glucocorticoids. Clin Pharmacol Ther 1982:32:566-571.
26. Verbemc AA, Frost C, Roorda RJ, ct al. One year treatment with salmeterol compared with beclomethasone in children with asthma. Am J Respir Crit Care Mcd 1997;156:688-695.
27. Wang X, Dockcry D, Wypil D, ct al. Pulmonary function between 6 and 18 years of age. Pediatr Pulmonol 1993:15: 75-88.
28. Mclvor RA, Hzzichini E, Turner МО, et al. Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Mcd 1998;158:924-930.
29. Kips JC, O'Connor BJ, Inman MD, et al. A long-term study on the antiinflammatory effect of low-dose budesonide plus for-moterol versus high-dose budesonide in asthma. Am J Respir Crit Care Med 2000;161:996-1001.
30. Veroerne AA, Frost C, Duivennan Ы, et al. Addition of salmeterol versus doubling the dose of beclomethasone in children with asthma. The Dutch Asthma Study Group. Am J Respir Crit Care Mcd 1998:158:213-219.
31. PDA Talk Paper. PDA requires new pediatric labeling for inhaled, intranasal corticosteroids. Rockville. MD: FDA, 1998.
32. Medicines Control Agency. The safety of inhaled and nasal corticosteroids. Curr Probl Pharmacovigilance 1998:24:5-10.
* Georgetown Place, Stockton, California.
* Southern California Research Center, Mission Viejo, California.
* Children Polyclinic, Moscow, Russia.
§ Hospital Argerich, Buenos Aires, Argentina. /1 Novartis Horsham Research Centre, Horsham, England. || Novartis Global Epidemiology, Barcelona, Spain. Данное исследование спонсировалось компанией Novartis. Исследователи получали оплату за проведение исследования, но не было заключено никаких финансовых соглашений, посредством которых результаты исследования могли бы повлиять на размер оплаты. У исследователей не было интересов собственности в отношении исследуемого продукта и значимых акционерных интересов в отношении компании-спонсора. МН Thomson, MD Till, and G Delia Cioppa постоянно работают в Novartis Pharmaceuticals. J Castellsague перевелся в Pharmacia, Spain. Received for publication April 25,2001. Accepted for publication in revised form February 19, 2002.
Уважаемый посетитель!
Чтобы распечатать файл, скачайте его (в формате Word).
Ссылка на скачивание - внизу страницы.